Saturday, May 5, 2007
Chair's Presentation Laurence H. Baker Chair, Southwest Oncology Group Professor, Internal Medicine & Pharmacology, University of Michigan Ann Arbor, Michigan
Consolidation with arsenic trioxide significantly improves event-free survival and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup Protocol C9710 Steven E. Coutre Associate Professor of Medicine, Stanford University School of Medicine
	Discussant Frederick R. Appelbaum Professor & Head, Div. of Medical Oncology, Univ. of Washington School of Medicine; Director, Clinical Research Div., Fred Hutchinson Cancer Research Center; Executive Director, Seattle Cancer Care Alliance
Cisplatin (cis)/etoposide vs. cis/irinotecan in extensive stage small cell lung cancer: pharmacogenomic and comparative toxicity analysis of JCOG 9511 and S0124 Primo N. Lara Professor of Medicine and Director, Clinical Trials Support Unit, UC Davis Cancer Center
	Discussant Peter O'Dwyer Director, Developmental Therapeutics Program, Abramson Cancer Center; Professor of Medicine, University of Pennsylvania
Pharmacogenics and breast cancer treatment outcomes: results on oxidative stress-related genotypes MPO and nSOD from a Southwest Oncology Group intergroup trial (INT-0102) Christine B. Ambrosone Director, Epidemiology, Roswell Park Cancer Institute; Associate Professor of Social and Preventive Medicine, University of Buffalo
	Discussant Carolyn Hoban Executive Officer, Southwest Oncology Group; Assistant Professor of Medicine, University of Michigan School of Medicine
Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: S0205 Philip. A. Philip Professor of Medicine, Wayne State University; Clinical Professor of Oncology, Karmanos Cancer Institute
	Discussant Richard L. Schilsky Chair, Cancer and Leukemia Group B; Professor of Medicine and Associate Dean of Clinical Research, University of Chicago